FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655232> ?p ?o ?g. }

• W4385655232 endingPage "e4428591" @default.
• W4385655232 startingPage "e4428591" @default.
• W4385655232 abstract "Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Mucosa-associated lymphoid tissue (MALT) lymphoma accounts for 7% of all non-Hodgkin lymphomas. Because of its indolent course and association to infectious agents (eg Helicobacter pylori-Hp) strategies such as watch-and-wait and antimicrobial therapy are justified in the frontline setting. In patients (pts) with localized disease, radiation therapy (RT) is widely applied with excellent local control whereas systemic therapy is usually reserved for those with advanced disease. Aims: To describe the clinical features, therapy patterns and outcomes of MALT lymphoma pts managed in Latin America. Methods: We designed a retrospective cohort study of pts from Latin America managed at 7 academic centers from 2001 to 2022. Pts data was manually abstracted from medical records in a standardized form. Overall survival (OS) was defined as the time from diagnosis to death from any cause, while progression-free survival (PFS) was defined as the elapsed time from diagnosis to relapse or disease progression or death from any cause. The Kaplan-Meier and the Log-rank test were employed to estimate and compare survival probabilities. Results: A total of 120 pts were identified, 47 (39%) from Peru, 25 (21%) Argentina, 21 (18%) Guatemala, 11 (9%) Cuba, 7 (6%) Uruguay, 5 (4%) Paraguay, 4 (3%) Colombia. Median age at diagnosis was 63 years (27-93) with slight female predominance (51%). Localized stage (I-II) at diagnosis was presented in 93 (78%) pts. Gastric and ocular adnexal were the most common disease sites (n=63, 52% and n=25, 21%, respectively). Primary cutaneous MALT was found in 8 (7%) pts. Infectious etiology with Hp, Chlamydia psittaci and Borrelia burgdorferi were identified in 65% (41/63), 4% (1/25) and 13% (1/8) of gastric, ocular adnexal and cutaneous MALT lymphoma, respectively. Other MALT cases had Hep C (n=2), IgG4 disease (n=3), Hashimoto thyroiditis (n=13) and Sjogren’s syndrome (n=9). Therapy patterns were heterogeneous. In localized stage, watch-and-wait (n=29, 31%) and single-agent rituximab (n=22, 24%) were the most common frontline approaches whereas R-CHOP (n=17, 63%) was common in advanced disease. Frontline RT alone was given to 14 (15%) pts with localized disease. Median RT dose was 24 Gy (4-40). In the entire cohort, the overall response rate (ORR) to frontline was 95% (CR 76%). With a median follow up of 45 months (37-55) the 4-year and median OS and PFS for the entire cohort was 84% and not reached (NR), and 60% and NR, respectively. Pts with localized MALT had significantly better 4-year OS (93 vs 55%, p<0.01) and PFS (69 vs 29%, p<0.01) than advanced stage (Figure). Second line therapy was used in 35 (39%) pts. ORR to second line were 97% (CR 74%). The 4-year and median OS in relapsed pts were 71% and NR. No patients received novel agents during their treatment course (ie BTK, clinical trial). Summary/Conclusion: To our knowledge, this is one of the largest cohorts of pts with MALT lymphoma in Latin America. We found most pts had localized disease with gastric and ocular adnexal as the most common sites. Common approaches in localized MALT were watch-and-wait and single-agent rituximab whereas R-CHOP in advanced stage. Response rates to frontline therapy were high in both localized and advanced MALT. However, outcomes were significantly superior in pts with localized disease. Few pts with localized MALT had frontline RT due to difficulty accessing such therapy in Latin America. We are currently prospectively evaluating pts with MALT lymphoma to better understand therapy patterns and access to novel agents across Latin American countries.Keywords: Indolent non-Hodgkin’s lymphoma" @default.
• W4385655232 created "2023-08-09" @default.
• W4385655232 creator A5010581104 @default.
• W4385655232 creator A5022086966 @default.
• W4385655232 creator A5025847424 @default.
• W4385655232 creator A5041674330 @default.
• W4385655232 creator A5043681121 @default.
• W4385655232 creator A5046572052 @default.
• W4385655232 creator A5047223130 @default.
• W4385655232 creator A5069417815 @default.
• W4385655232 creator A5072870394 @default.
• W4385655232 creator A5073605579 @default.
• W4385655232 creator A5075094334 @default.
• W4385655232 creator A5078221833 @default.
• W4385655232 creator A5081041058 @default.
• W4385655232 creator A5084688543 @default.
• W4385655232 creator A5091449486 @default.
• W4385655232 creator A5092611932 @default.
• W4385655232 creator A5092611933 @default.
• W4385655232 creator A5092611934 @default.
• W4385655232 date "2023-08-01" @default.
• W4385655232 modified "2023-10-18" @default.
• W4385655232 title "PB2264: CLINICAL FEATURES, TREATMENT PATTERNS, AND OUTCOMES AMONG 120 PATIENTS WITH MALT LYMPHOMA IN LATIN AMERICA: A STUDY FROM THE GRUPO DE ESTUDIO LATINOAMERICANO DE LINFOPROLIFERATIVOS (GELL)" @default.
• W4385655232 doi "https://doi.org/10.1097/01.hs9.0000975788.44285.91" @default.
• W4385655232 hasPublicationYear "2023" @default.
• W4385655232 type Work @default.
• W4385655232 citedByCount "0" @default.
• W4385655232 crossrefType "journal-article" @default.
• W4385655232 hasAuthorship W4385655232A5010581104 @default.
• W4385655232 hasAuthorship W4385655232A5022086966 @default.
• W4385655232 hasAuthorship W4385655232A5025847424 @default.
• W4385655232 hasAuthorship W4385655232A5041674330 @default.
• W4385655232 hasAuthorship W4385655232A5043681121 @default.
• W4385655232 hasAuthorship W4385655232A5046572052 @default.
• W4385655232 hasAuthorship W4385655232A5047223130 @default.
• W4385655232 hasAuthorship W4385655232A5069417815 @default.
• W4385655232 hasAuthorship W4385655232A5072870394 @default.
• W4385655232 hasAuthorship W4385655232A5073605579 @default.
• W4385655232 hasAuthorship W4385655232A5075094334 @default.
• W4385655232 hasAuthorship W4385655232A5078221833 @default.
• W4385655232 hasAuthorship W4385655232A5081041058 @default.
• W4385655232 hasAuthorship W4385655232A5084688543 @default.
• W4385655232 hasAuthorship W4385655232A5091449486 @default.
• W4385655232 hasAuthorship W4385655232A5092611932 @default.
• W4385655232 hasAuthorship W4385655232A5092611933 @default.
• W4385655232 hasAuthorship W4385655232A5092611934 @default.
• W4385655232 hasBestOaLocation W43856552321 @default.
• W4385655232 hasConcept C10515644 @default.
• W4385655232 hasConcept C126322002 @default.
• W4385655232 hasConcept C138885662 @default.
• W4385655232 hasConcept C143998085 @default.
• W4385655232 hasConcept C146357865 @default.
• W4385655232 hasConcept C151730666 @default.
• W4385655232 hasConcept C158886217 @default.
• W4385655232 hasConcept C167135981 @default.
• W4385655232 hasConcept C2776409635 @default.
• W4385655232 hasConcept C2777525834 @default.
• W4385655232 hasConcept C2779134260 @default.
• W4385655232 hasConcept C2779338263 @default.
• W4385655232 hasConcept C2779526237 @default.
• W4385655232 hasConcept C2779851268 @default.
• W4385655232 hasConcept C41895202 @default.
• W4385655232 hasConcept C509974204 @default.
• W4385655232 hasConcept C66339696 @default.
• W4385655232 hasConcept C71924100 @default.
• W4385655232 hasConcept C72563966 @default.
• W4385655232 hasConcept C86803240 @default.
• W4385655232 hasConceptScore W4385655232C10515644 @default.
• W4385655232 hasConceptScore W4385655232C126322002 @default.
• W4385655232 hasConceptScore W4385655232C138885662 @default.
• W4385655232 hasConceptScore W4385655232C143998085 @default.
• W4385655232 hasConceptScore W4385655232C146357865 @default.
• W4385655232 hasConceptScore W4385655232C151730666 @default.
• W4385655232 hasConceptScore W4385655232C158886217 @default.
• W4385655232 hasConceptScore W4385655232C167135981 @default.
• W4385655232 hasConceptScore W4385655232C2776409635 @default.
• W4385655232 hasConceptScore W4385655232C2777525834 @default.
• W4385655232 hasConceptScore W4385655232C2779134260 @default.
• W4385655232 hasConceptScore W4385655232C2779338263 @default.
• W4385655232 hasConceptScore W4385655232C2779526237 @default.
• W4385655232 hasConceptScore W4385655232C2779851268 @default.
• W4385655232 hasConceptScore W4385655232C41895202 @default.
• W4385655232 hasConceptScore W4385655232C509974204 @default.
• W4385655232 hasConceptScore W4385655232C66339696 @default.
• W4385655232 hasConceptScore W4385655232C71924100 @default.
• W4385655232 hasConceptScore W4385655232C72563966 @default.
• W4385655232 hasConceptScore W4385655232C86803240 @default.
• W4385655232 hasIssue "S3" @default.
• W4385655232 hasLocation W43856552321 @default.
• W4385655232 hasLocation W43856552322 @default.
• W4385655232 hasOpenAccess W4385655232 @default.
• W4385655232 hasPrimaryLocation W43856552321 @default.
• W4385655232 hasRelatedWork W1751802373 @default.
• W4385655232 hasRelatedWork W1917168805 @default.
• W4385655232 hasRelatedWork W1977130900 @default.
• W4385655232 hasRelatedWork W2025173475 @default.
• W4385655232 hasRelatedWork W2033265576 @default.
• W4385655232 hasRelatedWork W2120168784 @default.

• next